Merck nabs 'breakthrough' label for anti-melanoma drug

Merck ($MRK) won the FDA's "Breakthrough Therapy" tag for its experimental antibody drug lambrolizumab, aimed at advanced melanoma. The designation was based on Phase Ib data that showed significant early signs of antitumor activity in some patients with aggressive cases of the deadly skin cancer. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.